• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Medicinova Inc

    4/28/25 4:16:03 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNOV alert in real time by email
    DEFA14A 1 notice_card_2025_defa14a.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities

    Exchange Act of 1934 (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material Pursuant to §240.14a-12

     

     

    MEDICINOVA, INC

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required

    ☐ Fee paid previously with preliminary materials

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

     

     

     


    img85605900_0.jpg


    img85605900_1.jpg


    Get the next $MNOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNOV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MNOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Nagao Hideki

    4 - MEDICINOVA INC (0001226616) (Issuer)

    6/20/25 4:11:47 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lemerond Nicole

    4 - MEDICINOVA INC (0001226616) (Issuer)

    6/20/25 4:11:16 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Beaver Carolyn

    4 - MEDICINOVA INC (0001226616) (Issuer)

    6/20/25 4:10:52 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on MediciNova with a new price target

    Maxim Group initiated coverage of MediciNova with a rating of Buy and set a new price target of $15.00

    3/16/21 8:15:44 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on MediciNova with a new price target

    Maxim Group initiated coverage of MediciNova with a rating of Buy and set a new price target of $15.00

    3/10/21 7:48:19 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $MNOV
    SEC Filings

    View All

    MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

    LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code: 4875), today announced an update and the patients' basic characteristics data from its Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS), known as the COMBAT-ALS study. These results were presented at the 36th International Symposium on ALS/MND, held December 5–7, 2025, in San Diego, California, USA. The poster presentation, titled "COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Basic Characteristics" (Reference # CTL-21),

    12/8/25 6:00:00 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Message from the CEO to MediciNova Shareholders

    LA JOLLA, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dear Fellow Shareholders, Following the recent publication in the Journal of Atherosclerosis and Thrombosis, I would like to provide additional perspective on why this research represents a significant milestone for MediciNova and our MN-001 program. The study, conducted in collaboration with a leading Japanese academic research team, revealed a novel mechanism by MN-002, the primary metabolite of MN-001, enhances cholesterol efflux in macrophages through upregulation of ABCA1 and ABCG1 transporters. This mechanism is critical because cholesterol efflux is the first step in Reverse Cholesterol Transport (RCT)—the body's natural process

    12/1/25 6:00:00 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

    LA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), is pleased to announce the appointment of Dr. Christopher D. Breder, MD, PhD as Clinical and Regulatory Advisor. Dr. Breder will provide strategic guidance for MediciNova's Drug Development programs and will lead the Scientific Advisory Board upon its formation. Dr. Christopher D. Breder, MD, PhD, is a distinguished physician-scientist and regulatory expert with over two decades of experience across the U.S. Food and Drug Administration (FDA) and major pharmaceutical compa

    11/18/25 6:00:00 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Medicinova Inc

    EFFECT - MEDICINOVA INC (0001226616) (Filer)

    12/12/25 12:15:16 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Medicinova Inc

    S-3 - MEDICINOVA INC (0001226616) (Filer)

    12/5/25 4:23:58 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Medicinova Inc

    10-Q - MEDICINOVA INC (0001226616) (Filer)

    11/12/25 4:35:02 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNOV
    Leadership Updates

    Live Leadership Updates

    View All

    MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

    LA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), is pleased to announce the appointment of Dr. Christopher D. Breder, MD, PhD as Clinical and Regulatory Advisor. Dr. Breder will provide strategic guidance for MediciNova's Drug Development programs and will lead the Scientific Advisory Board upon its formation. Dr. Christopher D. Breder, MD, PhD, is a distinguished physician-scientist and regulatory expert with over two decades of experience across the U.S. Food and Drug Administration (FDA) and major pharmaceutical compa

    11/18/25 6:00:00 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Medicinova Inc (Amendment)

    SC 13D/A - MEDICINOVA INC (0001226616) (Subject)

    7/12/22 12:12:02 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care